Floatz logo

lum001

Cholestatic Liver Disease

Mirum Pharmaceuticals, Inc.Phase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Cholestatic Liver Disease cohort.

Asset / SponsorPhaseRating
Linerixibat
GlaxoSmithKline
Phase 3BB
URSODEOXYCHOLIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3B
Tauroursodeoxycholic
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Phase 3B
ERGOCALCIFEROLUM
Chulalongkorn University
Phase 4B

View all 24 →

Same molecule, other indications

lum001 is also rated in:

Alagille syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
progressive familial intrahepatic cholestasisDormant
B
Indicative ·
62 / 100
View asset →
Primary Biliary CirrhosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →